The Supreme Court of Canada ruled Friday that two drug stores in Ontario may not designate their own brand of generic drugs as “interchangeable” with the name-brand versions because it could lead to pharmacies sharing in the revenues of drug manufacturers.
A South Dakota federal judge on Tuesday supported a jury's finding against Johnson & Johnson on a negligence claim in a woman's lawsuit linking her cancer to the company's talcum body powder, though it still owes her no damages.
Direct mailers from Amgen Inc. oversold the benefits of anemia drug Aranesp and omitted important information about its potential to cause heart attacks and strokes, according to a U.S. Food and Drug Administration letter released Friday.
Chinese medical products company Shandong Weigao Group Medical Polymer Co. Ltd. said Thursday it is selling its entire 21.7 percent stake in medical device maker Biosensors International Group Ltd. for $312.3 million, citing a need to consolidate business.
Atlanta-based Taylor English Duma LLP has snagged a former Bryan Cave LLP pharmaceutical and medical device expert for the firm's new product liability group that is part of its litigation practice.
The Federal Circuit on Friday overturned the U.S. Patent and Trademark Office's rejection of claims in an inventor's patent application for a psoriasis treatment, finding the office failed to support its findings that the claims were invalid as anticipated and obvious.
Time Warner has a clear favorite between the two rival companies vying to merge with it, while a trio of private equity firms are chasing down a drugmaker worth $2 billion.
In Tuesday's hip implant deal, Johnson & Johnson took the unusual step of accepting responsibility for most of the plaintiffs' insurance liens for surgery costs, a promise that jacks up — perhaps substantially— its $2.5 billion tab, but removes an obstacle to resolution that has increasingly stymied defendants in mass tort litigation.
Health care providers already swamped by rank-and-file staffers launching False Claims Act suits are now coming under siege by new and unexpected whistleblowers, from consultants and in-house counsel to high-ranking executives, creating fresh pressure to respond swiftly and decisively to fraud allegations, experts say.
The reorganized Rotech Healthcare Inc. in Delaware bankruptcy court Monday filed a supplemental objection to Baker & McKenzie LLP's request for more than $1 million in fees, saying the firm withheld a significant conflict of interest with a Rotech lien holder from the court.
A third-party drug purchaser told a Pennsylvania federal judge on Wednesday that its class action alleging GlaxoSmithKline PLC subsidized illegal copayments for brand-name prescription drugs was legitimate, arguing that the pharmaceutical giant had no grounds to seek its dismissal.
Axinn Veltrop & Harkrider LLP made a new hire Monday for its intellectual property group in New York, tapping a skilled litigator from Curtis Mallet-Prevost Colt & Mosle LLP with expertise in an array of life science and technology sectors.
For the second time in three years, Kadmon Pharmaceuticals LLC has sent promotional literature with faulty information on safety and effectiveness, a "particularly troubling" repeat offense, the U.S. Food and Drug Administration said in a warning letter released Wednesday.
Hologic Inc., a maker of cancer-screening tools, acted fast on Wednesday to adopt a poison pill plan to protect itself against unwanted buyout campaigns, after activist investor Carl Icahn disclosed a sizable minority stake in the company.
A Massachusetts federal judge has rejected competing bids for summary judgment in a defibrillator patent dispute between Philips Electronics North American Corp. and Zoll Medical Corp., finding in an order published Tuesday that remaining issues of fact should be left to a jury to decide.
A Pennsylvania federal judge on Wednesday denied a bid to certify a proposed class of indirect purchasers who are accusing Warner Chilcott PLC of making small tweaks to its severe acne medication Doryx as a tactic to stave off generics.
Even with Tuesday's $2.5 billion settlement agreement, Johnson & Johnson still faces thousands of hip implant lawsuits from plaintiffs who haven't replaced the device, setting up more skirmishes over the company's liability for pain and other injuries unrelated to follow-up surgeries.
GNC Holdings Inc. and USPlabs LLC were sued Tuesday by a Hawaii woman who allegedly developed nonviral hepatitis after taking the fat-burning supplement OxyElite Pro, which the U.S. Food and Drug Administration has linked to a rash of illnesses in the state.
Twenty-five pharmaceutical firms, including Sandoz Inc. and Johnson & Johnson, will shell out a collective $88 million to resolve allegations in Louisiana court that they defrauded the state's Medicaid program by artificially inflating wholesale prices, capping a three-year legal saga that ensnared scores of other manufacturers, state officials said Wednesday.
The U.S. Food and Drug Administration on Wednesday advised health care providers to avoid two Astellas Pharma Inc. cardiac stress test drugs in patients with weaker hearts and strengthened the drugs' warning labels in response to reported instances of heart attack and death.
The French Sunshine Act, which requires national councils to disclose information submitted by affected enterprises that produce or market medications, medical devices and biomaterials about agreements with French health care professionals, has opened up many questions for debate and challenges for life sciences manufacturers who may be within the scope of the act, say attorneys with King & Spalding LLP.
In recent actions against a medical laboratory, a marketer of home-monitoring cameras and a mobile device manufacturer, the U.S. Federal Trade Commission has signaled its intent to expand its aggressive assertion of authority under the Federal Trade Commission Act’s “unfair trade practices” prong to regulate a broader range of data security practices and product design features, say attorneys with Ropes & Gray LLP.
Just as the U.S. Food and Drug Administration was starting to gain momentum on its food-oversight initiatives, the majority of its preventive and enforcement powers have been stalled by the U.S. federal government shutdown. Whether and how the FDA will gain back its food-oversight momentum that took 70 years to build remains to be seen, says Cori Annapolen Goldberg of Norton Rose Fulbright.
In its opinion in SIGA Technologies Inc. vs. PharmAthene Inc., the Delaware Supreme Court surveyed applicable law in a number of other jurisdictions, including New York, and distinguished several other cases on the basis that Delaware law did not apply. The opinion reinforces the importance of considering the relevant law to govern an agreement, since the choice could have real-world consequences, says Christopher Austin of Cleary Gottlieb Steen & Hamilton LLP.
President Obama seems to be of the view that if law school were reduced to two years, students would incur two-thirds of the expense of attending law school, be burdened by two-thirds of the debt they currently have, and be generally economically better off than they are today after three years of law school. Most startling about the president’s proposal, however, is that he did not discuss the educational effect of his suggestion on the students or the effect on their clients, says Fred Isquith of Wolf Haldenstein Adler Freeman & Herz LLP.
The U.S. District Court for the Southern District of California's recent opinion in Dorfman v. Nutramax highlights the broad reach of the state's Unfair Competition Law and Consumer Legal Remedies Act, which means that potential defendants should brace themselves for the big battle: defeating class certification, says Melody Akhavan of Weil Gotshal & Manges LLP.
When it comes to preventing cyberattacks, the U.S. government can’t protect its own networks, let alone those of large law firms. And when it comes to deterring and punishing intruders, our government offers even less. We have to do more than play defense. We didn’t reduce street crime by requiring pedestrians to buy better body armor every year, says Stewart Baker, a partner with Steptoe & Johnson LLP and former assistant secretary for policy at the U.S. Department of Homeland Security.
What should an attorney do in the middle of a deposition if her client answers in a way that suggests a misunderstanding of the question or sudden memory loss? She will likely want to confer with her client at the next available opportunity, but her ability to do so without waiving privilege will depend, in part, on where the deposition is taking place, say attorneys with Pillsbury Winthrop Shaw Pittman LLP.
The Supreme Court in MedImmune v. Genentech established that a declaratory judgment plaintiff need not "bet the farm" or "risk treble damages" before being able to seek a declaration that its acts do not violate another’s rights. Nonetheless, a line of Federal Circuit cases indicate a trend toward requiring declaratory judgment plaintiffs to do exactly that — "bet the farm" by risking substantial investments in the manufacture or sale of a potentially accused product, say Chris Ryan and Syed Fareed of Vinson & Elkins LLP.
A close read of Guenther v. Novartis reveals that the actions by the U.S. District Court for the Middle District of Florida appeared to have prepared the judge for the daily evidentiary battle likely to ensue at trial. The case also indicates that the best course may be to focus motions in limine on only a few pieces of key evidence, rather than the whole gamut of evidence you hope to exclude, says Adam Tolin of Weil Gotshal & Manges LLP.